XENE vs ACAD

ACADIA Pharmaceuticals Inc.

(ACAD) offers the better valuation at 9. 4x trailing P/E (48. 5x forward), making it the more compelling value choice. Analysts rate Xenon Pharmaceuticals Inc. (XENE) a "Buy" — based on 22 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Xenon Pharmaceuticals Inc.

(XENE) delivered a total return of +222. 8%, compared to +2. 5% for ACADIA Pharmaceuticals Inc. (ACAD). Over 10 years, the gap is even starker: XENE returned +775. 3% versus ACAD's -22. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Xenon Pharmaceuticals Inc.

(XENE) is the lower-risk stock at 1. 05β versus ACADIA Pharmaceuticals Inc. 's 1. 26β — meaning ACAD is approximately 20% more volatile than XENE relative to the S&P 500. On balance sheet safety, Xenon Pharmaceuticals Inc. (XENE) carries a lower debt/equity ratio of 1% versus 4% for ACADIA Pharmaceuticals Inc. — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc.

grew EPS 68. 4% year-over-year, compared to -44. 9% for Xenon Pharmaceuticals Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -46. 1% for Xenon Pharmaceuticals Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -49. 7% for XENE. At the gross margin level — before operating expenses — ACAD leads at 91. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ACAD: 61.

9% to $34. 78.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Xenon Pharmaceuticals Inc.

(XENE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 05), +775. 3% 10Y return). Both have compounded well over 10 years (XENE: +775. 3%, ACAD: -22. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: XENE is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.